Get the Stockscreener App
1.73
1.17%
0.02
After Hours:
1.73
Citius Oncology Inc stock is traded at $1.73, with a volume of 83,893.
It is up +1.17% in the last 24 hours and down -9.42% over the past month.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
See More
Previous Close:
$1.71
Open:
$1.71
24h Volume:
83,893
Relative Volume:
0.14
Market Cap:
$135.58M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.49%
1M Performance:
-9.42%
6M Performance:
+157.67%
1Y Performance:
+71.29%
1-Day Range:
$1.69
$1.7942
1-Week Range:
$1.69
$1.93
52-Week Range:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.73 | 142.81M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
142.26 | 62.54B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 43.30B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.08 | 40.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.02 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.06 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Upgrade | Maxim Group | Hold → Buy |
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Real time breakdown of Citius Oncology Inc. stock performanceGDP Growth & Weekly Market Pulse Alerts - newser.com
What to do if you’re stuck in Citius Oncology Inc.Trade Volume Report & High Return Stock Watch Alerts - newser.com
How Citius Oncology Inc. stock benefits from tech adoptionLayoff News & Accurate Intraday Trading Signals - newser.com
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Is Citius Oncology Inc. stock attractive for long term wealth buildingBuy Signal & Fast Moving Stock Watchlists - newser.com
Is Citius Oncology Inc. stock bottoming out2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
Is it too late to sell Citius Oncology Inc.July 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
Is Citius Oncology Inc. a candidate for recovery playStock Surge & Safe Swing Trade Setup Alerts - newser.com
Sector ETF performance correlation with Citius Oncology Inc.July 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
Heatmap analysis for Citius Oncology Inc. and competitors2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Why Citius Oncology Inc. stock is recommended by analystsJuly 2025 Summary & Verified Technical Signals - newser.com
Citius Oncology's (CTOR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
How Citius Oncology Inc. stock performs in stagflationTrade Risk Summary & Low Drawdown Trading Strategies - newser.com
Will a bounce in Citius Oncology Inc. offer an exitMarket Movement Recap & Safe Entry Zone Identification - newser.com
Has Citius Oncology Inc. formed a bullish divergenceVolume Spike & Daily Volume Surge Signals - newser.com
Is it time to cut losses on Citius Oncology Inc.Trade Volume Report & Real-Time Stock Price Movement Reports - newser.com
Citius in talks over Lymphir access in global markets - The Pharma Letter
Citius Sets Up Access to Lymphir in Southern Europe - MarketScreener
Citius Oncology expands LYMPHIR access through named patient programs - Investing.com
Citius Oncology enters exclusive distribution agreement with Integris Pharma S.A. - MarketScreener
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - PR Newswire
Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Decline in Short Interest - Defense World
Is a relief rally coming for Citius Oncology Inc. holdersWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com
Can volume confirm reversal in Citius Oncology Inc.July 2025 Highlights & Low Risk Entry Point Tips - newser.com
Using data tools to time your Citius Oncology Inc. exit2025 Earnings Impact & Technical Analysis for Trade Confirmation - newser.com
What MACD and RSI say about Citius Oncology Inc.Trade Risk Report & Long-Term Safe Return Strategies - newser.com
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Down 55.2% in September - MarketBeat
Citius Oncology (NASDAQ:CTOR) and Structure Therapeutics (NASDAQ:GPCR) Head to Head Survey - Defense World
Citius Oncology (CTOR) Price Target Increased by 100.00% to 6.12 - Nasdaq
Citius Oncology Inc Stock (CTOR) Financials Data
There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):